What Is BPC-157?

BPC-157, often called Body Protection Compound-157, is a synthetic pentadecapeptide related to a sequence found in gastric juice. It is widely discussed in wellness and sports-recovery communities, but it is not FDA-approved for human therapeutic use. Most evidence involves preclinical studies, animal models, and limited early human safety data.

How It Works

BPC-157 is studied for potential effects on tissue-related signaling, inflammation-related pathways, angiogenesis, and gastrointestinal or musculoskeletal repair models. The mechanism is not established as a proven clinical effect in humans.

What It’s Studied For

BPC-157 has been studied in preclinical models involving gastric tissue, tendon/ligament models, wound repair, inflammation, and musculoskeletal injury. Narrative reviews emphasize promising preclinical findings but limited robust human clinical evidence. FDA has identified safety concerns and insufficient information to determine human harm risk for compounded BPC-157 in certain contexts.

How It May Be Used in a Clinician-Supervised Program

A licensed provider may consider BPC-157 as part of a clinician-supervised recovery-support program when medically appropriate. Review may include injury history, surgery/procedure history, medications, immune issues, cancer history, pregnancy status, allergies, and expectations. It does not replace standard medical evaluation for pain, injury, gastrointestinal symptoms, or post-surgical care.

Preferred Starting Options / Dosing Notes

Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.

Safety Considerations

• Limited human data and uncertain long-term effects.
• Possible immune reactions, injection-site reactions, sterility/purity concerns.
• Unknown risk in pregnancy, cancer history, immune disorders, or complex medical conditions.
• FDA has cited concerns around immunogenicity, impurities, and inadequate safety information for BPC-157-related compounded products.

Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing.

Frequently Asked Questions